How do you feel the oral IL-23 (Icotyde) will shape psoriasis management?

As a first oral option with a specific targeted pathway differing from apremilast, minimal to no blood lab needs, no needle involvement, and once daily dosing, this medication is a dramatic shift for patients. Personally, I am hopeful for lower-age pediatric dosing. Looking forward to how this medic...

I think this new med will be the leading first-line systemic medication for psoriasis patients who have been inadequately controlled by topicals but are hesitant to go straight to a biologic. Systemic treatment-naive psoriasis patients will likely represent the largest population of new oral IL-23 s...